Cargando…
MR1-restricted T cells: the new dawn of cancer immunotherapy
Cancer immunotherapy has recently undergone rapid development into a validated therapy for clinical use. The adoptive transfer of engineered autologous T cells, such as chimeric antigen receptor (CAR) T cells, has been remarkably successful in patients with leukemia and lymphoma with cluster of diff...
Autores principales: | Wang, Zhiding, Wang, Mengzhen, Chen, Jinghong, Zhang, Linlin, Zhang, Li, Yu, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670570/ https://www.ncbi.nlm.nih.gov/pubmed/33185693 http://dx.doi.org/10.1042/BSR20202962 |
Ejemplares similares
-
One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia
por: Wang, Zhiding, et al.
Publicado: (2021) -
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
por: Wirth, Thomas C., et al.
Publicado: (2017) -
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
por: Deng, Zhuoya, et al.
Publicado: (2022) -
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
por: Tezera, Liku B, et al.
Publicado: (2020) -
Tonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiome
por: Marié, Isabelle J, et al.
Publicado: (2021)